Gene therapy targets in heart failure: The path to translation

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 4, 2011, Pages 542-553

  Raake, P W J ^a   Tscheschner, H ^a   Reinkober, J ^a   Ritterhoff, J ^a   Katus, H A ^a   Koch, W J ^b   Most, P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ADENYLATE CYCLASE IV; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C TERMINUS OF BETA ADRENERGIC RECEPTOR KINASE; CALCIUM ION; CATECHOLAMINE; G PROTEIN COUPLED RECEPTOR KINASE 2; INTRACELLULAR CALCIUM SENSING PROTEIN; LIPOSOME; MICRORNA; PARVALBUMIN; PARVOVIRUS VECTOR; PHOSPHOLAMBAN; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN S 100; S100A1 PROTEIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BINDING AFFINITY; CARDIOMYOPATHY; CELL DEATH; CELL SURVIVAL; DIASTOLIC DYSFUNCTION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPLACEMENT; GENE CASSETTE; GENE DOSAGE; GENE OVEREXPRESSION; GENE REPLACEMENT THERAPY; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENE VECTOR; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; INTRACELLULAR SIGNALING; MOLECULARLY TARGETED THERAPY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; RNA TRANSLATION; SYSTOLIC HEART FAILURE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENE TARGETING; GENE THERAPY; HEART FAILURE; HUMANS; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION;

EID: 80052967213     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.148     Document Type: Article

References (75)

1. Rockman, H.A., Koch, W.J. & Lefkowitz, R.J. Seven-transmembrane- spanning receptors and heart function. Nature 415, 206-212 (2002). (Pubitemid 34059526)
2. Penela, P., Ribas, C. & Mayor, F. Jr. Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cell. Signal. 15, 973-981 (2003). (Pubitemid 37130155)
3. Vinge, L.E., Raake, P.W. & Koch, W.J. Gene therapy in heart failure. Circ. Res. 102, 1458-1470 (2008).
4. Raake, P.W. et al. G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ. Res. 103, 413-422 (2008).
5. Koch, W.J. et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 268, 1350-1353 (1995).
6. Harding, V.B., Jones, L.R., Lefkowitz, R.J., Koch, W.J. & Rockman, H.A. Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. Proc. Natl. Acad. Sci. USA 98, 5809-5814 (2001). (Pubitemid 32435724)
7. White, D.C., Hata, J.A., Shah, A.S., Glower, D.D., Lefkowitz, R.J. & Koch, W.J. Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc. Natl. Acad. Sci. USA 97, 5428-5433 (2000). (Pubitemid 30313735)
8. Rengo, G. et al. Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 119, 89-98 (2009).
9. Williams, M.L. et al. Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts. Circulation 109, 1590-1593 (2004). (Pubitemid 38451713)
10. Brodde, O.E., Bruck, H. & Leineweber, K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J. Pharmacol. Sci. 100, 323-337 (2006). (Pubitemid 44609527)
11. Engelhardt, S., Grimmer, Y., Fan, G.H. & Lohse, M.J. Constitutive activity of the human beta(1)-adrenergic receptor in beta(1)-receptor transgenic mice. Mol. Pharmacol. 60, 712-717 (2001). (Pubitemid 32900252)
12. Noma, T. et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest. 117, 2445-2458 (2007).
13. Liggett, S.B. et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 101, 1707-1714 (2000). (Pubitemid 30196632)
14. Maurice, J.P. et al. Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. J. Clin. Invest. 104, 21-29 (1999). (Pubitemid 29534341)
15. Shah, A.S. et al. Intracoronary adenovirus-mediated delivery and overexpression of the beta(2)-adrenergic receptor in the heart: prospects for molecular ventricular assistance. Circulation 101, 408-414 (2000). (Pubitemid 30067398)
16. Steinberg, S.F. The molecular basis for distinct beta-adrenergic receptor subtype actions in cardiomyocytes. Circ. Res. 85, 1101-1111 (1999).
17. Roth, D.M. et al. Adenylyl cyclase increases survival in cardiomyopathy. Circulation 105, 1989-1994 (2002). (Pubitemid 34437629)
18. D'Angelo, D.D. et al. Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc. Natl. Acad. Sci. USA 94, 8121-8126 (1997). (Pubitemid 27343787)
19. T akahashi, T. et al. Increased cardiac adenylyl cyclase expression is associated with increased survival after myocardial infarction. Circulation 114, 388-396 (2006). (Pubitemid 44264820)
20. Lai, N.C. et al. Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation 110, 330-336 (2004). (Pubitemid 38955502)
21. Bers, D.M. Cardiac excitation-contraction coupling. Nature 415, 198-205 (2002). (Pubitemid 34059525)
22. Periasamy, M. & Kalyanasundaram, A. SERCA pump isoforms: their role in calcium transport and disease. Muscle Nerve 35, 430-442 (2007). (Pubitemid 46542962)
23. T akahashi, R. & Endoh, M. Dual regulation of myofilament Ca2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium. Br. J. Pharmacol. 145, 1143-1152 (2005). (Pubitemid 43079987)
24. del Monte, F. et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 100,2308-2311 (1999).
25. Schultz, J.e.l.J. et al. Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activity. Am. J. Physiol. Heart Circ. Physiol. 286, H1146-H1153 (2004).
26. Ito, K., Yan, X., Feng, X., Manning, W.J., Dillmann, W.H. & Lorell, B.H. Transgenic expression of sarcoplasmic reticulum Ca(2+) atpase modifies the transition from hypertrophy to early heart failure. Circ. Res. 89, 422-429 (2001). (Pubitemid 34132658)
27. Miyamoto, M.I. et al. Adenoviral gene transfer of SERCA2a improves leftventricular function in aortic-banded rats in transition to heart failure. Proc. Natl. Acad. Sci. USA 97, 793-798 (2000). (Pubitemid 30070389)
28. Hirsch, J.C., Borton, A.R., Albayya, F.P., Russell, M.W., Ohye, R.G. & Metzger, J.M. Comparative analysis of parvalbumin and SERCA2a cardiac myocyte gene transfer in a large animal model of diastolic dysfunction. Am. J. Physiol. Heart Circ. Physiol. 286, H2314-H2321 (2004). (Pubitemid 38685248)
29. Kawase, Y. et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J. Am. Coll. Cardiol. 51, 1112-1119 (2008). (Pubitemid 351374774)
30. Hajjar, R.J. et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J. Card. Fail. 14, 355-367 (2008). (Pubitemid 351756538)
31. C hu, G. & Kranias, E.G. Functional interplay between dual site phospholambam phosphorylation: insights from genetically altered mouse models. Basic Res. Cardiol. 97 (suppl. 1), I43-I48 (2002).
32. Pattison, J.S. et al. Phospholamban overexpression in transgenic rabbits. Transgenic Res. 17, 157-170 (2008). (Pubitemid 351421974)
33. Haghighi, K. et al. Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. J. Biol. Chem. 276, 24145-24152 (2001).
34. Sato, Y. et al. Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J. Biol. Chem. 276, 9392-9399 (2001).
35. Kiriazis, H. et al. Hypertrophy and functional alterations in hyperdynamic phospholamban-knockout mouse hearts under chronic aortic stenosis. Cardiovasc. Res. 53, 372-381 (2002). (Pubitemid 34117688)
36. Freeman, K. et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J. Clin. Invest. 107, 967-974 (2001). (Pubitemid 32323407)
37. Delling, U., Sussman, M.A. & Molkentin, J.D. Re-evaluating sarcoplasmic reticulum function in heart failure. Nat. Med. 6, 942-943 (2000).
38. Song, Q. et al. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J. Clin. Invest. 111, 859-867 (2003). (Pubitemid 37074961)
39. Iwanaga, Y. et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J. Clin. Invest. 113, 727-736 (2004). (Pubitemid 38544166)
40. Kaye, D.M. et al. Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J. Am. Coll. Cardiol. 50, 253-260 (2007). (Pubitemid 47031573)
41. del Monte, F., Harding, S.E., Dec, G.W., Gwathmey, J.K. & Hajjar, R.J. Targeting phospholamban by gene transfer in human heart failure. Circulation 105, 904-907 (2002). (Pubitemid 34184564)
42. Suckau, L. et al. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 119, 1241-1252 (2009).
43. Haghighi, K. et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111, 869-876 (2003). (Pubitemid 37074962)
44. Haghighi, K. et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc. Natl. Acad. Sci. USA 103, 1388-1393 (2006). (Pubitemid 43191175)
45. Most, P. et al. S100A1: a regulator of myocardial contractility. Proc. Natl. Acad. Sci. USA 98, 13889-13894 (2001). (Pubitemid 33115994)
46. Most, P. & Koch, W.J. S100A1: a calcium-modulating inotropic prototype for future clinical heart failure therapy. Future Cardiol. 3, 5-11 (2007). (Pubitemid 46157665)
47. Remppis, A. et al. Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy. Biochim. Biophys. Acta 1313, 253-257 (1996). (Pubitemid 26342956)
48. Most, P., Remppis, A., Pleger, S.T., Katus, H.A. & Koch, W.J. S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R568-R577 (2007). (Pubitemid 47205035)
49. Most, P. et al. Distinct subcellular location of the Ca2+-binding protein S100A1 differentially modulates Ca2+-cycling in ventricular rat cardiomyocytes. J. Cell. Sci. 118, 421-431 (2005). (Pubitemid 40277353)
50. Most, P. et al. Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J. Biol. Chem. 278, 33809-33817 (2003). (Pubitemid 37553215)
51. Pleger, S.T. et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 115, 2506-2515 (2007). (Pubitemid 46763224)
52. Vkers, M. et al. S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes. Cell Calcium 41, 135-143 (2007).
53. Brinks, M.H. et al. S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J. Am. Coll. Cardiol. (in press).
54. Steenaart, N.A., Ganim, J.R., Di Salvo, J. & Kranias, E.G. The phospholamban phosphatase associated with cardiac sarcoplasmic reticulum is a type 1 enzyme. Arch. Biochem. Biophys. 293, 17-24 (1992).
55. Gupta, R.C., Mishra, S., Rastogi, S., Imai, M., Habib, O. & Sabbah, H.N. Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am. J. Physiol. Heart Circ. Physiol. 285, H2373-H2381 (2003). (Pubitemid 37443053)
56. Pathak, A. et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ. Res. 96, 756-766 (2005). (Pubitemid 40559515)
57. C arr, A.N. et al. Type 1 phosphatase, a negative regulator of cardiac function. Mol. Cell. Biol. 22, 4124-4135 (2002). (Pubitemid 34556583)
58. Yamada, M. et al. Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. FASEB J. 20, 1197-1199 (2006).
59. Wehrens, X.H. et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 304, 292-296 (2004). (Pubitemid 38452182)
60. El-Armouche, A. et al. Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy. Cardiovasc. Res. 80, 396-406 (2008).
61. Periasamy, M. & Janssen, P.M. Molecular basis of diastolic dysfunction. Heart Fail. Clin. 4, 13-21 (2008). (Pubitemid 351289332)
62. Wahr, P.A., Michele, D.E. & Metzger, J.M. Parvalbumin gene transfer corrects diastolic dysfunction in diseased cardiac myocytes. Proc. Natl. Acad. Sci. USA 96, 11982-11985 (1999). (Pubitemid 29502844)
63. del Monte, F. et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation 104, 1424-1429 (2001). (Pubitemid 32880157)
64. Volkers, M., Loughrey, C.M., Macquaide, N., Remppis, A., DeGeorge, B.R. Jr., Wegner, F.V., et al. S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes. Cell Calcium 41,135-143 (2007). (Pubitemid 46014745)
65. Fukushima, H., Chung, C.S. & Granzier, H. Titin-isoform dependence of titinactin interaction and its regulation by S100A1/Ca2+ in skinned myocardium. J. Biomed. Biotechnol. 2010, 727239 (2010).
66. Narula, J. et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc. Natl. Acad. Sci. USA 96, 8144-8149 (1999). (Pubitemid 29328422)
67. C hesley, A. et al. The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase. Circ. Res. 87, 1172-1179 (2000).
68. Dong, H., Chen, Q., Sun, S., Yu, H. & Zhang, Z. Overexpression of beta(2)AR improves contractile function and cellular survival in rabbit cardiomyocytes under chronic hypoxia. Biochem. Biophys. Res. Commun. 398, 383-388 (2010).
69. P?icke, K., Heinroth-Hoffmann, I. & Brodde, O.E. Role of beta 1-and beta 2-adrenoceptors in hypertrophic and apoptotic effects of noradrenaline and adrenaline in adult rat ventricular cardiomyocytes. Naunyn Schmiedebergs Arch. Pharmacol. 367, 592-599 (2003).
70. Brinks, H. et al. Level of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro-and anti-apoptotic mechanisms. Circ. Res. 107, 1140-1149 (2010).
71. Kawada, T. et al. Rescue of hereditary form of dilated cardiomyopathy by rAAVmediated somatic gene therapy: amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters. Proc. Natl. Acad. Sci. USA 99, 901-906 (2002). (Pubitemid 34106608)
72. Goehringer, C. et al. Prevention of cardiomyopathy in delta-sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors. Cardiovasc. Res. 82, 404-410 (2009).
73. Muntoni, F., Torelli, S. & Ferlini, A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2, 731-740 (2003). (Pubitemid 37443515)
74. T ownsend, D., Blankinship, M.J., Allen, J.M., Gregorevic, P., Chamberlain, J.S. & Metzger, J.M. Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol. Ther. 15, 1086-1092 (2007). (Pubitemid 46813611)
75. Goyenvalle, A. et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306, 1796-1799 (2004) (Pubitemid 39601401)